Kornimate/medical-research-clean huggingface dataset:
left ventricular dysfunction post-surgical patent ductus arteriosus ligation in children: predictor factors analysis

Conditions: Congenital Heart Disease in Children

Summary: background: pda is viewed as a standout amongst the most widely recognized congenital heart defects in children and its closure is responsible for many hemodynamic changes that require intervention and care. methods: a retrospective study included fifty children with isolated pda treated by surgical ligation from june 2015 to june 2018. their mean age was 15.78 ± 7.58 months and 72% were females. the lv dimensions and systolic function were assessed by two-dimensional echocardiography pre pda ligation. the mean duct size was 4.08 ± 1.25 mm.

methods: study population fifty children with pda, for whom surgical pda ligation was done from june 2015 to june 2018. all cases were operated in cardiothoracic surgery department and were followed up by cardiothoracic surgeons and paediatricians at cardiac surgery icu, qena university hospital. their mean age at intervention was 15.78 ± 7.58 months, body surface area (bsa) 0.43±0.03 and 32 (72%) were females. the mean duct diameter was 4.08 ± 1.25 mm. the study conforms to the ethical standards of the helsinki declaration and approval was obtained from the institutional ethics committee of qena faculty of medicine. surgical technique pda ligation was performed under general anaesthesia after pre-operative anaesthetic evaluation. after single endotracheal tube anaesthesia induction; children were placed on the right lateral recumbent position fixed with adhesive plaster and a pad under the chest, the left arm raised above the head. a left mini-thoracotomy incision is done parallel to the medial border of the scapula and entrance to the thoracic cavity was via the third or fourth intercostal space. cautiously, the ductus is identified and dissected carefully. then it was doubly ligated with silk ligature (2/0 or 0). an intercostal tube inserted during operation and removed within 48 hours if no drainage presents. descriptive statistical analysis data were arranged and analyzed utilizing version 20 of the spss program (statistical package for social sciences). continuous variables were compared using the student paired t-test and are expressed as mean values ± standard deviation. pearson chi-square tests were used to detect differences among groups for categorical variables. the relationship between pda size and changes in echocardiographic parameters was verified using the pearson linear correlation and the linear regression analysis. p-value of \<0.05 was considered of significance.

Eligibility criteria:
inclusion criteria: * all cases had clinical as well as echocardiographic proof of hemodynamically critical pda. exclusion criteria: * patients with silent pda. * irreversible pulmonary vascular disease. * those who had associated hemodynamically significant congenital heart disease (chd).

Keywords: pda echo
clinical characteristics and subgroups in greater trochanteric pain syndrome

Conditions: Greater Trochanteric Pain Syndrome

Summary: this cross-sectional study will gather participant data from clinical assessment and questionnaires for individuals with a clinical diagnosis of greater trochanteric pain syndrome.

greater trochanteric pain syndrome (gtps) is characterised by pain over and around the greater trochanter and is primarily due to gluteal tendinopathy. pain associated with gtps can affect an individual's ability to perform daily activities while also having a negative impact on sleep, work and participation in sport. quality of life is often impaired and comparable to severe hip osteoarthritis. a significant number report chronic pain and disability with 29% and 45% of individuals continuing to experience pain at five and 11-year follow-up respectively. exercise programmes which specifically target the gluteal muscles and tendons are normally the first-line treatment for gtps, however 20-50% of individuals do not fully recover within 12 months with this intervention. the reasons for this poor response remain unclear but may be associated with the presence of certain clinical characteristics. diabetes, obesity, co-existing musculoskeletal disorders, psychological factors and physical activity level may affect prognosis and treatment outcome in gtps. co-existing low back and/or hip joint pain is common in this population and a higher number of pain sites has been associated with poorer outcome in other musculoskeletal conditions. in clinical trials, participants with gtps are often grouped together regardless of individual clinical characteristics. current treatment strategies appear inadequate for a proportion of patients with this condition meaning alternative options are required to achieve a positive clinical outcome. subgroups of patients within the same condition have been identified in low back pain, osteoarthritis and patellofemoral pain. thus, it is important to look for subgroups within the clinically diagnosed gtps population.

Eligibility criteria:
inclusion criteria: * adults aged \> 18 years who currently reside within greater glasgow and clyde * lateral hip pain of any duration * able to give written informed consent * pain on direct palpation of the gluteal tendon insertion on the greater trochanter and additionally at least one of the following pain provocation tests must also be positive: 1. faber (flexion, abduction, external rotation of the hip) 2. fader (flexion, adduction, external rotation of the hip) 3. fader and resisted internal rotation (ir) (fader position plus resisted ir of the hip) 4. single leg stand for 30 seconds 5. resisted hip abduction at end-range adduction exclusion criteria: * lateral hip pain secondary to another source e.g. hip joint pathology or lumbar referred pain * inflammatory joint conditions * neurological conditions * pregnancy * unable or unwilling to give informed consent * unable to write, read or comprehend english
genetic investigations in spontaneous coronary artery dissection (scad)

Conditions: Spontaneous Coronary Artery Dissection; SCAD

Summary: the purpose of the research is to identify mutations (defects in the genetic blueprint) that cause spontaneous coronary artery dissection (scad), in other words, spontaneous tears in blood vessels that supply the heart. some mutations may be inherited (passed on) from a parent without an apparent blood vessel problem while others may develop for the first time in the affected person.

study question: do mutations within certain genes cause or confer susceptibility to spontaneous coronary artery dissection (scad)? specific aims: 1. create a genomic dna and plasma biobank for individuals diagnosed with scad. 2. identify inherited and de novo/new mutations that underlie scad. 3. identify common genetic variants that confer risk for scad. long term objective:discover molecular and cellular mechanisms of scad and develop biomarkers to enable prediction and prevention. the purpose of the research is to identify mutations (defects in the genetic blueprint) that cause tears in blood vessels that supply the heart. some mutations may be inherited (passed on) from a parent without an apparent blood vessel problem while others may develop for the first time in the affected person. the study includes individuals diagnosed with spontaneous coronary artery dissection, their biological parents, and relatives with fibromuscular dysplasia, arterial aneurysm, or arterial dissection. adults with scad will be identified both retrospectively and prospectively.confirmation of the diagnosis by review of coronary angiography will be required before proceeding with the informed consent process and blood or saliva sample procurement.

Eligibility criteria:
inclusion criteria: * men and women able to give informed consent and complete a 2 page questionnaire * diagnosis of one or more episodes of spontaneous coronary artery dissection (scad) * biological parent of individual with scad * relative with fibromuscular dysplasia, arterial aneurysm, or arterial dissection exclusion criteria: * lack of confirmation of scad diagnosis

Keywords: spontaneous coronary artery dissection scad
analgesic efficacy, safety and tolerability of two paracetamol-containing solutions in post-surgical dental pain

Conditions: Pain, Postoperative

Summary: the aim of the study is to evaluate the therapeutic efficacy and safety of two different paracetamol-containing solutions in postoperative dental pain. they will be compared to placebo (a dummy treatment which contains no active ingredient).


Eligibility criteria:
inclusion criteria: * asa i or ii and scheduled for elective surgical extraction of 1 or more impacted mandibular 3rd molars, at least 1 of which must be a fully or partially impacted mandibular 3rd molar requiring mandibular bone removal. * moderate or severe pain within 4 hours after the completion of surgery. exclusion criteria: * another acute or chronic painful physical condition * use of any other analgesics (within 24 hours), sedatives, or narcotic drugs as well as microsomal enzyme inducers * inability to use and understand visual analog scale and verbal rating score

Keywords: pain, postoperative surgery, oral surgery, dental
registry for multiple endocrine neoplasia syndromes: men1/men2

Conditions: Multiple Endocrine Neoplasia Syndromes

Summary: objectives: to contribute new and prospective data to our existing database library for patients with men1 and men2 at the university of texas m.d. anderson cancer center.

previously followed men1 and men2 patients at m.d. anderson cancer center will be mailed an introductory letter and a "consent to be contacted" form to determine whether they are interested in participating in the study. new men1 and men2 patients seen in clinic at m.d. anderson cancer center will be asked if they wish to learn more about this study. interested patients will also be asked to distribute the introductory letter and consent to be contacted form to their blood relatives. printed materials regarding this study will only be mailed to non-mdacc individuals with the expressed written or verbal permission from a consenting mdacc patient. all interested individuals will return the signed "consent to be contacted" form to the pi. consented individuals will be interviewed by phone and/or mail to obtain updated family and medical history specific to their diagnosis of either men1 or men2. to verify accuracy of medical data collected, all non-mdacc participants will be asked if they consent to have their off-site medical records released to us for review. there will be no treatment or collection of blood or tissue in this study. although this study presents minimal risk to participants, participant consent will be obtained due to the need to obtain permission to make contact with patients and their families. approximately 1500 patients and their relatives will be included in this study. this will be done on an inpatient and outpatient basis.

Eligibility criteria:
inclusion criteria: 1. registered mdacc patients diagnosed with men1 or men2. 2. close relatives of registered mdacc men patients. exclusion criteria: 1. individuals who are either non-mdacc registered patients or do not have a close relative who is an men patient registered at mdacc.

Keywords: multiple endocrine neoplasia syndromes men1 men2 relatives database questionnaires surveys
indirect comparison topotecan cervical carcinoma

Conditions: Cervical Intraepithelial Neoplasia

Summary: indirect comparisons were performed using data from gog-0179 versus gog-0169 to permit comparison of topotecan in combination with cisplatin versus cisplatin plus paclitaxel via the common comparator of cisplatin monotherapy. both gog-0179 and gog-0169 were conducted in patients with stage ivb, recurrent or persistent carcinoma of the cervix, but there were some differences between the respective study populations. patients with prior chemotherapy were eligible for gog-0179 but ineligible for gog-0169 (except when chemotherapy was used for radiation sensitisation). fewer patients had received chemotherapy as a radiosensitiser in gog-0169 (27%) than in gog-0179 (\~60%) and these patients were unevenly distributed between treatment arms in gog-0169. in addition, the proportion of patients receiving cisplatin as a radiosensitiser in gog-0169 is unknown. for these reasons, there are limitations associated with the indirect meta-analysis.


Eligibility criteria:
inclusion criteria: * randomised clinical trials, or systematic reviews and meta-analyses * treatment with topotecan or platinum-based single and combination regimens in female patients of any race with cancer of the cervix recurrent after radiotherapy or stage ivb disease exclusion criteria: * none
phase ii study of fractionated 90y ibritumomab tiuxetan (zevalin) radioimmunotherapy as an initial therapy of follicular lymphoma

Conditions: Follicular Lymphoma

Summary: 90y ibritumomab tiuxetan (zevalin) has demonstrated consistently high response rates in patients who have received previous treatment for lymphoma. more than two-thirds of the patients who achieve cr go on to experience durable remissions lasting for years. despite these highly promising clinical results with radioimmunotherapy (rit) in relapsed follicular lymphoma there is very little data using rit in previously untreated follicular lymphoma. the objective of this trial is to evaluate the safety and efficacy of two fractions of zevalin in patients with previously untreated follicular lymphoma in a phase ii study.


Eligibility criteria:
inclusion criteria: * patients must have a histologically confirmed cd20 +ve follicular lymphoma grades i to iiia. * patients with at least one of the following symptoms requiring initiation of treatment: (as outlined by the modified bnli/gelf criteria below) * nodal mass \> 7cm in its greater diameter * b symptoms * elevated serum ldh or beta2-microglobulin * involvement of at least 3 nodal sites (each with a diameter \> 3 cm) * symptomatic splenic enlargement * compressive syndrome * patients must have an ecog performance status less than or equal to 2 and an anticipated survival of at least 6 months. * patients must have an absolute granulocyte count of above 1,500/mm3, and a platelet count of above 100,000/mm3 post 4 weeks of unlabelled rituximab. a hemoglobin \>= 8.0 g/dl * patients must have adequate renal function (defined as calculated creatinine clearance \> 30 ml/mn), hepatic function (defined as total bilirubin \<1.5 times upper limit of normal), and hepatic transaminases (defined as ast \<5 times upper limit of normal) * patients must have given informed consent prior to study entry. exclusion criteria: * patients with a mean of \>20% of the intratrabecular marrow space involved with lymphoma on bone marrow biopsy following induction rituximab therapy. * transformed follicular lymphoma and discordant lymphoma * patients with active obstructive hydronephrosis. * patients with initial disease bulk greater than 10cm. * patients with evidence of active infection requiring i.v. antibiotics at the time of study entry. * patients with congestive heart failure stage iii or iv of nyha classification, myocardial infraction or unstable angina within 6 months or other serious illness that would preclude evaluation. * patients with left vef \< 40% * patients with large pleural or peritoneal effusions. * patients with known hiv infection or active hbv (hbsag positivity) or hcv infection. * known hypersensitivity to murine antibodies or proteins * patients who are pregnant or breast-feeding. male and female patients must agree to use effective contraception for 12 months following 90y-ibritumomab tiuxetan antibody therapy. * patients with prior malignancy other than lymphoma, except for adequately-treated skin cancer, cervical cancer in situ, or other cancer for which the patient has been disease-free for 5 years.
evaluation of the effects of irrigation of the extraction socket with rifamycine

Conditions: Impacted Third Molar Tooth

Summary: removal of impacted lower third molar teeth is one of the most common oral surgical procedures, and these operations often lead to various complications in patients. antibiotics, analgesics and mouthwashes are prescribed for the treatment of complications encountered. when using postoperative antibiotics in surgery of impacted third molar teeth, lower surgical area infection, pain, swelling and trismus are seen. based on this information, in this study, it is aimed to evaluate the effects of rifamycine intraoperatively on the postoperative pain, swelling and trismus.


Eligibility criteria:
inclusion criteria: * absence of any systemic disease * having bilateral impacted mandibular third molar teeth in a similar position * absence of allergy to any of the drugs used in the study, * absence of pregnancy/lactating state, * no history of any medication use during at least 2 week before the operation. exclusion criteria: * not regularly coming to the controls, * not using their medicines regularly * using any additional medication that may affect the outcome of the study

Keywords: rifamycine pain edema trismus
safety and tolerability study of shp626 in overweight and obese adults

Conditions: Non-Alcoholic Steatohepatitis

Summary: this study will investigate the safety and tolerability of daily dosing regimens of shp626 in overweight and obese adults.


Eligibility criteria:
inclusion criteria: * males that comply with any applicable contraceptive requirements or females of non-childbearing potential * no history of active or chronic disease other than that allowed by study (hypertension, hyperlipidemia and gerd or heartburn) * has a body mass index of 25-35 kg/m2 with a body weight of greater than 140lbs (assessed at screening) exclusion criteria: * no history of alcohol or substance abuse, including use of tobacco * no substantial changes in eating habits or exercise routine.
virtual reality training for aphasia rehabilitation

Conditions: Anomic Aphasia

Summary: aphasia is an acquired deficit following acute damage to the central nervous system that involves the difficulty or impossibility of understanding and formulating language. a typical disorder of non-fluent forms of aphasia is anomia. anomia refers to the difficulty in finding words, in particular when trying to name objects and actions. according to the embodied cognition approach (ec), language is tightly connected to the motor system. in this view, language rehabilitation programs should stimulate language through the activation of the motor system. in this approach, since anomic deficits are often due to a weak link between the meaning of the word and its lemma, the hebbs' principles of coincident and correlated learning can be exploited, i.e., by intensifying the synchronous activation of lexicon and semantics and connecting them with the motor counterpart. in this study, the investigators present an innovative training, based on the ec framework, in which they will make use of new technologies for anomia rehabilitation in post-stroke patients. specifically, the researchers will use immersive 360° videos representing everyday actions displayed from the first-person point of view, experienced through a head-mounted display. the training will be administered 3 times a week for 4 weeks. the control group will watch standard videos representing the same actions recorded from the third-person perspective. naming abilities will be tested before and after the training together with other cognitive and psychological measures. the investigators expect that the group who will undergo the 360° video-based training will show greater improvement of performance compared to the control group.


Eligibility criteria:
inclusion criteria: * naming disorder in the post-acute phase (index event occurring at least 6 months earlier) * to have already received rehabilitation treatment in the acute phase * noun naming below cut-off * verbs naming below cut- off exclusion criteria: * concomitant or pre-existing (with respect to the index event) neurological and psychiatric deficits * epilepsy * balance disorders * neglect

Keywords: virtual reality embodied cognition rehabilitation
setting up a covid-19 care facility at a prison in pakistan

Conditions: COVID-19

Summary: presenting outline of the steps taken by our team to set up a covid care facility within the prison setting. the facility was set up at camp jail (lahore district jail) located on ferozpur road, lahore.

a prisoner brought to camp jail developed symptoms of and later tested positive for covid-19. this lead to almost 527 contacts. an outbreak was expected. to manage the situation , a covid-19 care facility was established within the prison. the study describes the steps taken by the team to set up this facility.

Eligibility criteria:
inclusion criteria: - all covid-19 positive prisoners within the camp jail exclusion criteria: * any patient being shifted to any other facility (except designated)

Keywords: covid-19 prison pakistan
protective effect of statin against negative cardiovascular remodeling and organ dysfunction after acute aortic syndrome surgery (panda iii)

Conditions: Acute Aortic Syndrome; Aortopathy

Summary: acute aortic syndrome (aas)/aortic aneurysm is a common feature of aortic wall events, including aortic dissection, intramural hematoma, aortic ulceration and aortic trauma, and occurs in up to 35 cases per 100,000 cases per year between the ages of 65 and 75 years. increased levels of the inflammatory biomarker high-sensitivity c-reactive protein predict cardiovascular events. since statins lower levels of high-sensitivity c-reactive protein as well as cholesterol, the authors hypothesized that people with acute aortic syndrome but without hyperlipidemia might benefit from statin treatment.


Eligibility criteria:
inclusion criteria: * (1) patients with aortic dissection/ulceration/intermural hematoma/aortic aneurysm who underwent aortic arch replacement or endoluminal isolation or hybrid therapy; * (2) paitents without clinically significant hyperlipidemia but with cardiovascular disease risk factors (such as male ≥45 years old, female ≥55 years old, hypertension, diabetes, chronic kidney disease, obesity, low hdl cholesterol, smoking, alcohol consumption, family history of early onset ischemic cardiovascular disease) and no previous use of statins; * (3) patients are between 18 and 85 years old, male or female; * (4) agree to participate in the study and sign the informed consent. exclusion criteria: * (1) patients with allergy to statins; * (2) patients with active liver disease; * (3) patients with myopathy; * (4) lactating women and pregnant women; * (5) patients with mental diseases, drug and alcohol dependence; * (6) refuse to participate in the study or sign the informed consent.
relationship between cardiovascular disease in asthma and eosinophil subtypes and biomarkers of bronchial remodeling.

Conditions: Asthma; Cardiovascular Diseases

Summary: to know the clinical and inflammatory characteristics of patients with asthma and associated cardiovascular disease.

recent studies have shown that asthma could be a risk factor for cardiovascular disease, especially in the female and late-onset subgroups. the two entities share several risk factors, such as chronic inflammation and bronchial remodeling. eosinophilia, characteristic of asthma, has also been described as a predictor of cardiovascular mortality. the aim of this study is to determine the clinical and inflammatory characteristics of patients with asthma and associated cardiovascular disease, as well as their relationship with eosinophil subtypes, biomarkers of chronic inflammation and bronchial remodeling.

Eligibility criteria:
inclusion criteria: * previous diagnosis of asthma * signed informed consent exclusion criteria: * age under 18 years old * age over 99 years old * pneumological diseases other than asthma * active oncological diseases or with end of treatment \<5 years * autoimmune or systemic inflammatory diseases

Keywords: asthma cardiovascular diseases chronic inflammation bronchial remodeling eosinophilia